Continuous treat-to-target ULT superior to discontinuation for gout remission: GO TEST FINALE

Clinical response with guselkumab linked to reduced structural damage progression in active and erosive PsA: The APEX study

Sequential romosozumab-denosumab provided greater BMD gains over 48 months in high-risk GC users

Bimekizumab demonstrates superior joint efficacy vs. risankizumab in active PsA: 24-week results from the BE-BOLD study